drugset
drugset / Trial / NCT05607693

A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects

NCT05607693 ↗

Phase 1 Unknown 52 enrolled Jiangsu HengRui Medicine Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether daily treatment with SHR3680 affects the ventricular repolarization in participants with Castration-Resistant Prostate Cancer (CRPC).

Timeline

Start
2023-04-26
Primary completion
2024-11-05
Completion
2024-11-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Rezvilutamide Small molecule 240 mg Oral

Indications

castration-resistant prostate carcinoma